Finland joins other Nordic nations in curbing Moderna shots

Finland has joined other Nordic countries in suspending or discouraging the use of Moderna’s COVID-19 vaccine in certain age groups because of an increased risk of heart inflammation, a rare side effect associated with the shot

Via AP news wire
Friday 08 October 2021 10:56
Philanthropy-Vaccine-Misinformation
Philanthropy-Vaccine-Misinformation

Finland has joined other Nordic countries in suspending or discouraging the use of Moderna s COVID-19 vaccine in certain age groups because of an increased risk of heart inflammation, a rare side effect associated with the shot.

The Finnish Institute for Health and Welfare said Thursday that authorities won't give the shot to males under age 30. They will be offered the Pfizer BioNTech vaccine instead. The government agency said it found that young men and boys were at a slightly higher risk of developing myocarditis.

The move by Finland followed similar decisions by three neighboring countries on Wednesday. Sweden suspended the use of Moderna for people under 30, Denmark said those under 18 won’t be offered the Swiss-made vaccine, and Norway urged those under 30 to get the Pfizer vaccine instead.

All four countries based their decision on an unpublished study with Sweden’s Public Health Agency saying that it signals “an increased risk of side effects such as inflammation of the heart muscle or the pericardium” — the double-walled sac containing the heart and the roots of the main vessels. It added: “The risk of being affected is very small.”

The preliminary information from the Nordic study has been sent to the European Medicines Agency’s adverse reaction committee to be assessed.

___

Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in